Research Grade Sotigalimab,5mg,HB782116-5mg,Abinscience

The FDA has granted an orphan drug designation to sotigalimab (APX005M) as a potential therapeutic option for patients with soft tissue sarcoma, according to announcement from Apexigen Inc., the drug developer. A novel, humanized monoclonal antibody, sotigalimab was designed stimulate antitumor immune response and to target CD40, which is a key co-stimulatory receptor that serves to activate innate and adaptive immune systems. When sotigalimab binds to CD40 on antigen-presenting cells, it induces a multifaceted immune response that brings several components of the immune system together to attack the cancer.

Host species	Humanized
Isotype	IgG1-Kappa
Species reactivity	Human
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4.
Purity	>95% as determined by SDS-PAGE.
Clonality	Monoclonal
Applications	Research Grade Biosimilar
Target	Tumor necrosis factor receptor superfamily member 5, B-cell surface antigen CD40, Bp50, CD40L receptor, TNFRSF5, CDw40, CD40
Purification	Protein A/G purified from cell culture supernatant.
Endotoxin level	Please contact with the lab for this information.
Expression system	Mammalian Cells
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names	APX005M, APX-005, APX-005-M, APX-005M, CAS: 2305607-45-6
Note	For research use only. Not suitable for clinical or therapeutic use.